As Co-CSCs are hypothesised to be central for tumour relapse and progression (Brabletz et al, 2005; Ricci-Vitiani et al, 2008), we investigated CD133 expression in a collection of colorectal adenocarcinomas that was highly stratified towards patient outcome. This evidence concerns the gene PROM1 and colorectal adenocarcinoma.